These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

843 related items for PubMed ID: 28870573

  • 1. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P, Losy J, Kramer L, Wójcicka M, Kaufman E.
    J Neurol Sci; 2017 Sep 15; 380():22-26. PubMed ID: 28870573
    [Abstract] [Full Text] [Related]

  • 2. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.
    Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, Murai H, Kira J.
    PLoS One; 2013 Sep 15; 8(4):e61835. PubMed ID: 23637915
    [Abstract] [Full Text] [Related]

  • 3. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
    Stilund M, Gjelstrup MC, Petersen T, Møller HJ, Rasmussen PV, Christensen T.
    PLoS One; 2015 Sep 15; 10(4):e0119681. PubMed ID: 25860354
    [Abstract] [Full Text] [Related]

  • 4. Prognostic relevance of the C-X-C motif chemokine ligand 13 and interleukin-8 in predicting the transition from clinically isolated syndrome to multiple sclerosis.
    Klíčová K, Mareš J, Sobek O, Rous Z, Rous M, Raška M, Hartung HP.
    Eur J Neurosci; 2024 Jun 15; 59(11):2955-2966. PubMed ID: 38453679
    [Abstract] [Full Text] [Related]

  • 5. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
    Obradović D, Kataranovski M, Dincić E, Obradović S, Colić M.
    Vojnosanit Pregl; 2012 Feb 15; 69(2):151-6. PubMed ID: 22500369
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Neurosyphilis Patients.
    Wang C, Wu K, Yu Q, Zhang S, Gao Z, Liu Y, Ni L, Cheng Y, Guan Z, Shi M, Lu H, Lou Y, Zhou P.
    Sci Rep; 2016 Sep 21; 6():33569. PubMed ID: 27650493
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
    Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmeström C, Piehl F, Olsson T, Lycke J.
    J Neurochem; 2017 Apr 21; 141(2):296-304. PubMed ID: 27787906
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis.
    Marastoni D, Magliozzi R, Bolzan A, Pisani AI, Rossi S, Crescenzo F, Montemezzi S, Pizzini FB, Calabrese M.
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov 21; 8(6):. PubMed ID: 34588298
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. CCL5, CXCL10 and CXCL11 chemokines in patients with active and stable relapsing-remitting multiple sclerosis.
    Szczuciński A, Losy J.
    Neuroimmunomodulation; 2011 Nov 21; 18(1):67-72. PubMed ID: 20720435
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.